A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)

doi:10.3760/cma.j.cn371439-20190926-00023

Abstract

Abstract:

Immune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers. So predictive markers are required to guide treatment decisions. The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. The pre-treatment LIPI is a convenient prognostic marker able to idenjpgy ICIs-treated patient groups with significantly different survival and response outcomes.

Key words: Carcinoma,non-small-cell lung, Prognosis, Immune checkpoint inhibitor, Lung immune prognostic index

Zhang Aixia, Sun Yahong. A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)[J]. Journal of International Oncology, 2020, 47(5): 301-303.

References 20

[1]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018,359(6382):1350-1355. DOI: 10.1126/science.aar4060. doi: 10.1126/science.aar4060 pmid: 29567705
[2]	Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance[J]. Exp Mol Med, 2018,50(8):109. DOI: 10.1038/s12276-018-0130-1. doi: 10.1038/s12276-018-0130-1 pmid: 30135516
[3]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639. DOI: 10.1056/NEJMoa1507643. doi: 10.1056/NEJMoa1507643 pmid: 26412456
[4]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi: 10.1056/NEJMoa1504627 pmid: 26028407
[5]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. doi: 10.1016/S0140-6736(15)01281-7 pmid: 26712084
[6]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016,375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi: 10.1056/NEJMoa1606774 pmid: 27718847
[7]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial[J]. Lancet, 2017,389(10066):255-265. DOI: 10.1016/S0140-6736(16)32517-X. doi: 10.1016/S0140-6736(16)32517-X pmid: 27979383
[8]	Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers[J]. Br J Cancer, 2017,117(7):913-920. DOI: 10.1038/bjc.2017.274. doi: 10.1038/bjc.2017.274 pmid: 28950287
[9]	Prelaj A, Tay R, Ferrara R, et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer[J]. Eur J Cancer, 2019,106:144-159. DOI: 10.1016/j.ejca.2018.11.002. doi: 10.1016/j.ejca.2018.11.002 pmid: 30528799
[10]	Peters S, Gettinger S, Johnson ML, et al. Phase Ⅱ trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)[J]. J Clin Oncol, 2017,35(24):2781-2789. DOI: 10.1200/JCO.2016.71.9476. doi: 10.1200/JCO.2016.71.9476 pmid: 28609226
[11]	Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase Ⅱ open-label study of atezolizumab in PD-L1-selected patients with NSCLC[J]. J Thorac Oncol, 2018,13(11):1733-1742. DOI: 10.1016/j.jtho.2018.05.004. doi: 10.1016/j.jtho.2018.05.004 pmid: 29775807
[12]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674. DOI: 10.1016/j.cell.2011.02.013. doi: 10.1016/j.cell.2011.02.013
[13]	Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer[J]. Onco Targets Ther, 2016,9:4879-4886. DOI: 10.2147/OTT.S107279. doi: 10.2147/OTT.S107279 pmid: 27540301
[14]	Laird BJ, Fallon M, Hjermstad MJ, et al. Qualityof life in patients with advanced cancer: differential association with performance status and systemic inflammatory response[J]. J Clin Oncol, 2016,34(23):2769-2775. DOI: 10.1200/JCO.2015.65.7742. doi: 10.1200/JCO.2015.65.7742 pmid: 27354484
[15]	McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer[J]. Cancer Treat Rev, 2013,39(5):534-540. DOI: 10.1016/j.ctrv.2012.08.003. doi: 10.1016/j.ctrv.2012.08.003 pmid: 22995477
[16]	Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018,4(3):351-357. DOI: 10.1001/jamaoncol.2017.4771. doi: 10.1001/jamaoncol.2017.4771 pmid: 29327044
[17]	Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials[J]. J Thorac Oncol, 2019,14(8):1440-1446. DOI: 10.1016/j.jtho.2019.04.006. doi: 10.1016/j.jtho.2019.04.006 pmid: 30999110
[18]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016,387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 pmid: 26970723
[19]	Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small-cell lung cancer[J]. JAMA Oncol, 2019,5(10):1481-1485. DOI: 10.1001/jamaoncol.2019.1747. doi: 10.1001/jamaoncol.2019.1747
[20]	Kim YJ, Kim CH, Lee SH, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced NSCLC treated with immune checkpoint inhibitor[J]. J Thorac Oncol, 2019,14(9):1608-1618. DOI: 10.1016/j.jtho.2019.05.033. doi: 10.1016/j.jtho.2019.05.033 pmid: 31195179